Caladrius Biosciences Opens Study of CLBS119 to Repair COVID-19-Induced Lung Damage
Caladrius Biosciences (Nasdaq: CLBS) has initiated a clinical trial for CLBS119, targeting COVID-19-induced lung damage. The study, taking place at NYU Langone Health, aims to evaluate the safety and efficacy of a single administration of CLBS119, a therapy using CD34+ cells. This proof-of-concept trial will include 12 patients suffering from hypoxia following SARS-CoV-2 infection. The Chief Medical Officer emphasized the unmet medical need for treatments that can repair long-term lung damage caused by COVID-19.
- Initiation of a clinical trial for CLBS119 targeting COVID-19-induced lung damage.
- Study aims to address a significant unmet medical need for COVID-19 survivors needing supplemental oxygen.
- Use of CD34+ cells shows potential for vascular repair based on previous clinical trials.
- The study is limited to a small sample size of 12 patients, raising concerns about the robustness of the results.
- There are no existing therapies that have conclusively shown to repair COVID-19-induced lung damage.
Patient screening begins immediately at NYU Langone Health
The study will explore the ability of CLBS119 to restore normal oxygen levels in patients who have recovered from the virus but require continued supplemental oxygen due to COVID-19-induced vascular damage
BASKING RIDGE, N.J., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced that it has opened its proof-of-concept study of CLBS119 as a treatment for COVID-19-induced lung damage and begun screening prospective patients for inclusion at NYU Langone Health. This planned 12-patient open-label clinical trial is designed to evaluate the safety and efficacy of a single administration of CLBS119 (peripheral blood-derived autologous CD34+ cells) for the treatment and repair of COVID-19-induced lung damage in adults. The study will target patients who are experiencing hypoxia due to prior infection with SARS-CoV-2 and who require supplemental oxygen.
“Evidence suggests that severe lung damage due to COVID-19 may lead to long-term disability as a result of vascular damage. Although many therapies are targeting the SARS-CoV-2 virus or the reduction of severe inflammation caused by the virus during the acute phase of the illness, no therapy has been shown to repair COVID-19-induced long-term lung damage,” said Douglas W. Losordo, M.D., FACC, FAHA, Chief Medical Officer at Caladrius. “In previous clinical trials and preclinical models, CD34+ cells consistently have shown evidence of vascular repair in multiple organs including models of severe lung damage. This clinical study of CLBS119 will address the significant unmet medical need for COVID-19 survivors who still require supplemental oxygen. Our hypothesis is that CD34+ cells can regenerate the blood vessels damaged by COVID-19, thereby restoring lung function and capacity and reducing or eliminating the need for supplemental oxygen.”
For more information on this study, please visit clinicaltrials.gov (identifier: NCT04522817). If you are a patient or a physician and have questions about eligibility for this study, please contact us at CLBS119@caladrius.com.
About Caladrius Biosciences
Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease. We are developing first- in-class cell therapy products based on the notion that our body contains finely tuned mechanisms for self-repair. Our technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication.
The Company’s current product candidates include CLBS119, a CD34+ cell therapy product candidate for the repair of lung damage in patients with COVID-19 who are experiencing respiratory failure, for which the Company recently initiated a clinical trial as well as three developmental treatments for ischemic diseases based on its CD34+ cell therapy platform: HONEDRA® (formerly CLBS12), recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (“CLI”) based on the results of an ongoing clinical trial; CLBS16, the subject of a recently completed positive Phase 2a clinical trial in the U.S. and slated to begin a comprehensive Phase 2b trial in the U.S. during 4Q20 for the treatment of coronary microvascular dysfunction (“CMD”); and CLBS14, a Regenerative Medicine Advanced Therapy (“RMAT”) designated therapy for which the Company has finalized with the U.S. Food and Drug Administration (the “FDA”) a protocol for a Phase 3 confirmatory trial in subjects with no-option refractory disabling angina (“NORDA”). For more information on the company, please visit www.caladrius.com.
Contact:
Investors:
Caladrius Biosciences, Inc.
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: +1-908-842-0084
Email: jmenditto@caladrius.com
Media:
W2O Group
Christiana Pascale
Phone: +1-212-257-6722
Email: cpascale@w2ogroup.com
FAQ
What is Caladrius Biosciences' new clinical study about CLBS119?
Where is the patient screening for the CLBS119 study taking place?
How many patients will be included in the CLBS119 trial?
What type of cells does CLBS119 use for treatment?
What is the goal of the CLBS119 study?
